News Search & Analytics
US Edition
Minimum 3 characters required!!
Report Based On Past 7 Days Data
10
Total Articles
8
Total Publisher Covering articles
6
Highest On 2017-10-19
0
Articles Got Popular On Social Media
gilead sciences found in Articles in last 7 Days

Top Articles

Shares of health-care companies rose as traders bet the sector would fare well in earnings season. Shares of Gilead Sciences rose after the Food and Drug Administration approved a ...
Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy
-InvestorPlace - Fri Oct 13 08:03:34 EDT 2017
Markets barely reacted when Gilead Sciences Inc. (NASDAQ:) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The lack of a reaction is understandable: Ki...
3 Healthcare Value Stocks | Fox Business
-Fox Business - Fri Oct 13 14:41:57 EDT 2017
When value investors search through 10-Ks and valuation ratios for stocks selling on the cheap, healthcare isn't typically a sector full of stocks selling at a deep discount. ...
Gilead Sciences' (NASDAQ: GILD) recently approved Yescarta could be a billion-dollar blockbuster cancer-cell therapy, but the company could face stiff competition from Celgene...
Gilead Sciences (GILD) Sales Growth Hampers Rating
-InvestorPlace - Mon Oct 16 11:15:02 EDT 2017
Portfolio Grader currently ranks Gilead Sciences Inc (NASDAQ:GILD) a Hold. The methods for fundamental and quantitative metrics used in this analytical tool, developed by Louis Nav...
It’s Time to Start Buying Beaten-Up Gilead Sciences, Inc. (GILD) Stock
-InvestorPlace - Fri Oct 13 08:29:02 EDT 2017
Back in 2015, Hillary Clinton sent out a tweet promising to tackle price gouging, and that about marked the end of a secular bull market for biotech stocks. The iShares NASDAQ...
Is AbbVie the Best Dividend Stock in Healthcare? | Fox Business
-Fox Business - Fri Oct 13 14:41:58 EDT 2017
AbbVie (NYSE: ABBV) is making headway toward diversifying itself away from its best-selling drug, Humira, but Humira still accounts for most of its sales and that makes buying AbbV...
Purloined Portfolio features JP Morgan, NetEase
-tribLive - Mon Oct 16 20:51:24 EDT 2017
Updated 2 hours ago I call it the Purloined Portfolio. Once a year, based on government filings, I highlight a few stocks owned by other money managers I like or admire. This thiev...
(Reuters) - The Trump Administration threw its support behind a public-private partnership with 11 drug companies to advance a new class of drugs that uses the body’s immune system...
I call it the Purloined Portfolio. Once a year, based on government filings, I highlight a few stocks owned by other money managers I like or admire and make piggyback recommendati...
Celgene down 6% after discontinuing Crohn's disease trials
-Market Watch - Thu Oct 19 14:07:36 EDT 2017
Celgene Corp. was downgraded to neutral at Baird Equity Research on Friday after the drugmaker abandoned three Crohn's disease drug trials late Thursday. Baird analyst Brian Skorne...
Indexes close higher on a slow day
-Philly.com - Thu Oct 19 17:43:46 EDT 2017
A last-minute surge nudged U.S. stock indexes mostly higher Thursday, barely extending the market's winning streak and milestone-setting run. The Standard & Poor's 500 index an...
Stocks’ last-minute rebound nudges S&P 500 and Dow to new highs
-Los Angeles Times - Thu Oct 19 14:31:55 EDT 2017
A last-minute surge nudged U.S. stock indexes mostly higher Thursday, barely extending the market's winning streak and milestone-setting run. The Standard & Poor's 500 index an...
Last-minute rebound lifts S&P 500, Dow edge to new highs
-tribLive - Thu Oct 19 14:34:21 EDT 2017
Updated 8 hours ago A last-minute surge nudged U.S. stock indexes mostly higher Thursday, barely extending the market's winning streak and milestone-setting run. The Standard &...
The Food and Drug Administration approved a second version of a groundbreaking treatment Wednesday that genetically alters patients' cells to attack cancer - this time, to fight ag...
Advertisement